Cardiac surgery market to reach over $4.4 billion by 2017

NewsGuard 100/100 Score

According to a new report by iData Research (www.idataresearch.net), the leading global authority in medical device and pharmaceutical market research, percutaneous aortic valve replacement (PAVR) and percutaneous mitral valve repair (PMVR) devices are expected to enter the U.S. market in 2011 and grow to almost $1.3 billion by 2017. Adoption of these devices for treating mitral regurgitation, aortic stenosis and aortic insufficiency will fuel the overall U.S. cardiac surgery market to over $4.4 billion by 2017.  Companies such as Medtronic and Edwards Lifesciences are expected to be the first suppliers of PAVR and PMVR devices for the U.S. market.

"Approximately 1.2 million people in the U.S. have malfunctioning aortic valves and advances in diagnostic technologies, such as CT and MRI are increasing the diagnosis rates" says Dr. Kamran Zamanian, CEO of iData. "PAVR allows for aortic valve replacement without the need for open surgery, increasing patient safety and reducing recovery times. However the lack of long-term clinical data, complexity and high-cost of the procedure may limit initial adoption."

The report states that PAVR products by Medtronic and Edwards are available on the market in Europe, while U.S. clinical trials are currently underway. PMVR products by Evalve for the treatment of mitral regurgitation are also approved in Europe and pending FDA approval.

"Mitral valve disorders are usually diagnosed in patients over 65 and physicians are reluctant to perform open surgery if other comorbidities exist," says Dr. Zamanian. "PMVR procedures allow for a larger number of patients to be treated, leading to a CAGR of over 60% by 2017."

iData's report series on the U.S., European and Asian "Markets for Cardiac Surgery Devices" includes: tissue and mechanical heart valves, annuloplasty repair, PMVR, PAVR, ONCAB, OPCAB, endoscopic vessel-harvesting, cardiac ablation, transmyocardioal revascularization, intra-aortic balloons, artificial hearts, anastomosis-assist, ventricular-assist, PFO, ASD and VSD devices.

SOURCE iData Research Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Smoking, drinking, and dietary habits linked to head and neck cancer risk, study finds